The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Loncastuximab tesirine: a novel antibody-drug conjugate for DLBCL
Carmelo Carlo-Stella, MD, PhD, of Humanitas Clinical and Research Center, Rozzano, Italy, discusses initial results of a Phase II study of loncastuximab tesirine, a novel antibody-drug conjugate targeting CD19, in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
